Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
|Podcasts|May 26, 2021
Neoadjuvant and Adjuvant Treatment of HER2-Positive Breast Cancer
Author(s)OncLive Staff
Dr Kaklamani and colleagues take an in-depth look at data from select clinical trials in the neoadjuvant and adjuvant settings for patients with HER2-positive breast cancer.
Advertisement
Advertisement
Related to this article
Check out this September recap of OncLive’s coverage of the top news and expert insights in breast cancer.
The FDA approved tucatinib plus trastuzumab and pertuzumab as maintenance for advanced HER2-positive breast cancer after induction.
Experts spotlight the variety of breast cancer research being presented at the 2026 ESMO Congress.
The FDA approved atezolizumab plus chemo for stage III colon cancer, cleared a tucatinib-based maintenance regimen for advanced breast cancer, and more.
The liquid biopsy identifies ESR1 mutations in blood to select patients with metastatic breast cancer who may be eligible for treatment with camizestrant.
China's approval of Dato-DXd for TNBC was supported by TROPION-Breast02 data showing a median OS of 23.7 months vs 18.7 months with chemotherapy.
The NMPA approved T-DXd after neoadjuvant therapy, based on DESTINY-Breast05 data, in which the agent lowered the risk of recurrence or death vs T-DM1.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Breakthrough Device Designation to Natera’s Multi-Cancer Early Detection Assay
2
Targeted Approaches in Pancreatic Cancer, Chemo Intensification in CRC Take Center Stage as Key GI Oncology Presentations at ESMO 2026
3
FDA Approves Atezolizumab Plus Chemo for Stage III dMMR Colon Cancer
4
Next-Generation NAMPT Inhibitors Aim to Revive a Stalled Target in AML and MDS
5